Personalized medicine approaches in epilepsy

A commonSCN1Asplice-site polymorphism modifies the effect of carbamazepine on cortical excitability-A pharmacogenetic transcranial magnetic stimulation study

(2014) Katja Menzler et al.   EPILEPSIA

Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions

(2014) Ursula Amstutz et al.   EPILEPSIA

Ancestry-based pharmacogenomics, adverse reactions and carbamazepine: is the FDA warning correct?

(2014) P W Payne   PHARMACOGENOMICS JOURNAL

Management of focal epilepsy in adults treated with polytherapy in France: The direct cost of drug resistance (ESPERA study)

(2014) M. de Zélicourt et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

Disulfide-Containing High Mobility Group Box-1 Promotes N-Methyl-d-Aspartate Receptor Function and Excitotoxicity by Activating Toll-Like Receptor 4-Dependent Signaling in Hippocampal Neurons

(2013) Silvia Balosso et al.   ANTIOXIDANTS & REDOX SIGNALING

SCN1AIVS5-91G>A polymorphism is associated with susceptibility to epilepsy but not with drug responsiveness

(2013) Ritu Kumari et al.   BIOCHIMIE

Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma

(2013) Chiharu Tabata et al.   BMC CANCER

Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome

(2013) D. Kudo et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

The Long-Term Safety of Antiepileptic Drugs

(2013) Athanasios Gaitatzis et al.   CNS DRUGS

The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs

(2013) Michael A. Rogawski   EPILEPSIA

Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand

(2013) Waranya Rattanavipapong et al.   EPILEPSIA

Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital

(2013) Daniel J. Antoine et al.   HEPATOLOGY

Serum HMGB1 as a Diagnostic Marker for Malignant Peritoneal Mesothelioma

(2013) Chiharu Tabata et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Receptor for Advanced Glycation Endproducts is upregulated in temporal lobe epilepsy and contributes to experimental seizures

(2013) Valentina Iori et al.   NEUROBIOLOGY OF DISEASE

Absence of SLC2A1 Mutations Does Not Exclude Glut1 Deficiency Syndrome

(2013) Joerg Klepper   NEUROPEDIATRICS

SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis

(2013) Batoul Sadat Haerian et al.   PHARMACOGENOMICS

HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis

(2013) E Genin et al.   PHARMACOGENOMICS JOURNAL

A Multi-System Approach Assessing the Interaction of Anticonvulsants with P-gp

(2013) David Dickens et al.   PLoS One

GLUT1 deficiency syndrome 2013: Current state of the art

(2013) Valentina De Giorgis et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

Cost minimization of HLA-B*1502 screening before prescribing carbamazepine in Thailand

(2013) Somsak Tiamkao et al.   International Journal of Clinical Pharmacy

Glucose transporter 1 deficiency in the idiopathic generalized epilepsies

(2012) Todor Arsov et al.   ANNALS OF NEUROLOGY

Circulating high-mobility group box 1 and cardiovascular mortality in unstable angina and non-ST-segment elevation myocardial infarction

(2012) Tousei Hashimoto et al.   ATHEROSCLEROSIS

Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome

(2012) A. Brunklaus et al.   BRAIN

HLA Genotype and Carbamazepine-Induced Cutaneous Adverse Drug Reactions: A Systematic Review

(2012) V L Yip et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Human leukocyte antigen-associated drug hypersensitivity

(2012) Patricia T Illing et al.   CURRENT OPINION IN IMMUNOLOGY

T-cell receptor and carbamazepine-induced Stevens–Johnson syndrome and toxic epidermal necrolysis: understanding a hypersensitivity reaction

(2012) Tai-Ming Ko et al.   Expert Review of Clinical Immunology

Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients

(2012) Yvonne Nadine Fahmueller et al.   INTERNATIONAL JOURNAL OF CANCER

Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome

(2012) Chun-Yu Wei et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4

(2012) Milena Schiraldi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Adverse effects of antiepileptic drugs

(2012) Piero Perucca et al.   LANCET NEUROLOGY

Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial

(2012) Laura Bonnett et al.   LANCET NEUROLOGY

Immune self-reactivity triggered by drug-modified HLA-peptide repertoire

(2012) Patricia T. Illing et al.   NATURE

Pharmacogenetic tests: the need for a level playing field

(2012) Munir Pirmohamed et al.   NATURE REVIEWS DRUG DISCOVERY

Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore

(2012) D. Dong et al.   NEUROLOGY

Systems genetics in “-omics” era: current and future development

(2012) Hong Li   THEORY IN BIOSCIENCES

Cerebral expression of drug transporters in epilepsy

(2011) Eleonora Aronica et al.   ADVANCED DRUG DELIVERY REVIEWS

Activation of toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development

(2011) E. Zurolo et al.   BRAIN

Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy

(2011) Amit K. Tiwari et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Cost of disorders of the brain in Europe 2010

(2011) Anders Gustavsson et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome

(2011) Tai-Ming Ko et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan

(2011) Pei Chen et al.   NEW ENGLAND JOURNAL OF MEDICINE

HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans

(2011) Mark McCormack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy

(2010) Maria Paola Canevini et al.   EPILEPSIA

Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population

(2010) Takeshi Ozeki et al.   HUMAN MOLECULAR GENETICS

NaV1.1 channels and epilepsy

(2010) William A. Catterall et al.   JOURNAL OF PHYSIOLOGY-LONDON

Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures

(2010) Mattia Maroso et al.   NATURE MEDICINE

Absence epilepsies with widely variable onset are a key feature of familial GLUT1 deficiency

(2010) S. A. Mullen et al.   NEUROLOGY

Childhood Chorea With Cerebral Hypotrophy

(2009) Belén Pérez-Dueñas et al.   ARCHIVES OF NEUROLOGY

The expanding phenotype of GLUT1-deficiency syndrome

(2009) Knut Brockmann   BRAIN & DEVELOPMENT

Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies

(2009) Patrick Kwan et al.   EPILEPSIA

Early life seizures cause long-standing impairment of the hippocampal map

(2009) Havisha B. Karnam et al.   EXPERIMENTAL NEUROLOGY

Increased High Mobility Group Box-1 Protein Levels are Associated With Impaired Cardiopulmonary and Echocardiographic Findings After Acute Myocardial Infarction

(2009) Plinio Cirillo et al.   JOURNAL OF CARDIAC FAILURE

Transcriptome Profiling Reveals TGF-  Signaling Involvement in Epileptogenesis

(2009) L. P. Cacheaux et al.   JOURNAL OF NEUROSCIENCE

Temperature- and age-dependent seizures in a mouse model of severe myoclonic epilepsy in infancy

(2009) J. C. Oakley et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Association betweenSCN1Apolymorphism and carbamazepine-resistant epilepsy

(2008) Tomohide Abe et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A role for leukocyte-endothelial adhesion mechanisms in epilepsy

(2008) Paolo F Fabene et al.   NATURE MEDICINE

Cost of Epilepsy

(2008) Adam Strzelczyk et al.   PHARMACOECONOMICS

Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression

(2008) Patrick Kwan et al.   Pharmacogenetics and Genomics

HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis

(2008) Nahoko Kaniwa et al.   PHARMACOGENOMICS

Carbamazepine,HLA-B*1502and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations

(2008) P Brent Ferrell et al.   PHARMACOGENOMICS

Intrinsic Severity as a Determinant of Antiepileptic Drug Refractoriness

(2008) Michael A. Rogawski et al.   Epilepsy Currents

Innate and adaptive immunity during epileptogenesis and spontaneous seizures: Evidence from experimental models and human temporal lobe epilepsy

(2007) Teresa Ravizza et al.   NEUROBIOLOGY OF DISEASE